Vera Therapeutics Gears Up for Major Investor Conferences
Vera Therapeutics, Inc. (Nasdaq: VERA), a cutting-edge biotechnology company, is making waves in the healthcare sector with its commitment to advancing transformative treatments tailored for patients grappling with severe immunological diseases. With a solid foundation in late-stage clinical development, Vera Therapeutics is set to engage with investors through key presentations and one-on-one meetings at several forthcoming investor conferences.
Overview of Upcoming Conferences
The firm’s leadership team will participate in the following notable events:
8th Annual Evercore Healthcare Conference
This prestigious conference is designed to facilitate insightful discussions, featuring a fireside chat format alongside one-on-one meetings for deeper engagement. The company is scheduled to present on Tuesday, December 2, 2025, at 8:45 AM ET. The webcast for this event will be accessible online, providing an efficient way for stakeholders to engage with Vera Therapeutics’ innovative outlook and achievements.
Citi 2025 Global Healthcare Conference
Shortly after, participating in the Citi Global Healthcare Conference on Wednesday, December 3, 2025, at 4:00 PM ET will further expand Vera Therapeutics' visibility among investors and industry leaders. Similar to the Evercore Conference, this event will also incorporate a fireside chat and the opportunity for personalized meetings with management.
Post-Conference Access to Webcasts
A replay of the webcasts from both conferences will be made available for 90 days post-event. Interested parties can find these recordings in the Investor Calendar section of the Vera Therapeutics website, ensuring that anyone unable to attend the live presentations can still stay informed about the company’s advancements.
About Vera Therapeutics
Vera Therapeutics is at the forefront of developing targeted treatments aimed at altering the standard care for serious immunological conditions. The company works diligently to advance its lead therapeutic candidate, atacicept. This innovative drug is self-administered at home through a weekly subcutaneous injection, inhibiting both BAFF and APRIL, which are pivotal in stimulating B cell activity responsible for producing problematic autoantibodies linked to autoimmune diseases like IgA nephropathy (IgAN) and lupus nephritis.
Expanding its focus beyond IgAN, Vera Therapeutics is investigating additional disorders where atacicept's action could lead to meaningful clinical improvements. Furthermore, the company is excited about its exclusive license for VT-109, a next-generation fusion protein, that holds promise across a spectrum of B-cell mediated diseases.
Additionally, Vera Therapeutics is developing MAU868, an innovative monoclonal antibody designed to combat the alarming effects of BK virus infections, especially in kidney transplant patients. Vera Therapeutics proudly claims all global rights related to the development and commercialization of atacicept, VT-109, and MAU868, positioning itself as a leader in the biopharmaceutical landscape.
Contact Information
Investor Contact:
Joyce Allaire
LifeSci Advisors
212-915-2569
jallaire@lifesciadvisors.com
Media Contact:
Debra Charlesworth
Vera Therapeutics
415-854-8051
corporatecommunications@veratx.com
Frequently Asked Questions
What type of diseases does Vera Therapeutics focus on?
Vera Therapeutics concentrates on developing treatments for serious immunological diseases, targeting conditions like IgA nephropathy and lupus nephritis.
When will the upcoming investor conferences take place?
The 8th Annual Evercore Healthcare Conference will be on December 2, 2025, and the Citi 2025 Global Healthcare Conference will follow on December 3, 2025.
How can investors access the conference webcasts?
The webcasts will be available for 90 days after the conferences, accessible through the Investor Calendar on the Vera Therapeutics website.
What is atacicept, Vera Therapeutics’ lead drug candidate?
Atacicept is a fusion protein designed to block proteins that stimulate B cells, effectively targeting the underlying issues in autoimmune diseases.
Who can I contact for more information about Vera Therapeutics?
For investor inquiries, Joyce Allaire from LifeSci Advisors is available. For media inquiries, Debra Charlesworth at Vera Therapeutics can be contacted.